Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.

BACKGROUND Parathyroid hormone (PTH) measurements serve as a noninvasive, diagnostic tool for the assessment of renal osteodystrophy (ROD). Their value has been questioned following reports indicating that all commercially available intact PTH (I-PTH) assays cross-react with amino terminally truncated PTH fragments. Because these fragments can account for 50% of total PTH, their detection will overestimate the true PTH concentration and may lead to diagnostic inaccuracies. The aim of this study was to evaluate the specific Bio-Intact PTH (1-84) Assay (BI-PTH) in patients with various types of ROD confirmed by bone biopsy. METHODS Bone biopsies were taken from 132 patients with chronic kidney disease (CKD) stages 3 to 5, and quantitative bone histomorphometry was done. Plasma PTH levels were measured using both the BI-PTH and I-PTH assays on an automated analyzer. RESULTS Patients with CKD stages 3/4 and low turnover skeletal lesions had BI-PTH values (pg/mL, mean +/- SD) of 35 (+/-34) and I-PTH values of 59 (+/- 63). Corresponding values for BI-PTH and I-PTH in those with high turnover lesions were 141 (+/-60) and 221 (+/-106). Patients with CKD stage 5 and low turnover skeletal lesions had BI-PTH and I-PTH levels of 51 (+/-38) and 90 (+/-60), respectively, whereas the corresponding results for BI-PTH and I-PTH in those with high turnover lesions were 237 (+/-214) and 461 (+/-437). The areas under the receiver operating characteristic (ROC) curves for distinguishing low turnover from high turnover lesions were 0.94 for BI-PTH and 0.91 for I-PTH in CKD stages 3/4 and 0.86 for BI-PTH and 0.85 for I-PTH in CKD stage 5. Among all patients, BI-PTH levels are approximately 50% lower than I-PTH levels, but the results of the two assays are correlated highly (R2 = 0.92). CONCLUSION Plasma PTH measurements using either the BI-PTH or I-PTH assay effectively identify patients with reduced bone turnover and serve to distinguish this subgroup from those with high turnover lesions of renal bone disease. Both assays provide better diagnostic discrimination for this purpose than calculated values for the ratio of PTH (1-84)/amino terminally truncated PTH fragments.

[1]  A. Huber,et al.  An automated 'bio-intact' PTH assay: a step towards standardisation and improved correlation with parathyroid function in renal disease. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[2]  H. Malluche,et al.  The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. Inaba,et al.  Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. , 2004, Clinical chemistry.

[4]  K. Martin,et al.  Parathyroid hormone: new assays, new receptors. , 2004, Seminars in nephrology.

[5]  Keith C. Norris,et al.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  A. Meikle,et al.  Comparison of two third-generation parathyroid hormone assays. , 2003, Clinical chemistry.

[7]  E. Bonucci,et al.  Renal Osteodystrophy in Predialysis and Hemodialysis Patients: Comparison of Histologic Patterns and Diagnostic Predictivity of Intact PTH , 2002, Nephron.

[8]  Ethan M Balk,et al.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  Sudhaker D. Rao,et al.  Development of a Novel Immunoradiometric Assay Exclusively for Biologically Active Whole Parathyroid Hormone 1–84: Implications for Improvement of Accurate Assessment of Parathyroid Function , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  A. Dusso,et al.  A novel mechanism for skeletal resistance in uremia. , 2000, Kidney international.

[11]  H. Jüppner,et al.  A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. , 1999, The Journal of clinical endocrinology and metabolism.

[12]  C. Lazure,et al.  A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples. , 1998, Clinical chemistry.

[13]  R. Lepage,et al.  Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. , 1996, The Journal of clinical endocrinology and metabolism.

[14]  A. Canteros,et al.  Staining of bone aluminium: comparison between aluminon and solochrome azurine and their correlation with bone aluminium content. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. Monier‐Faugere,et al.  Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  Mei Wang,et al.  Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  M. Monier‐Faugere,et al.  The role of bone biopsy in the management of patients with renal osteodystrophy. , 1994, Journal of the American Society of Nephrology : JASN.

[18]  G. Segre,et al.  Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. , 1994, Kidney international.

[19]  D. Sherrard,et al.  Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. , 1993, Kidney international.

[20]  Y. Pei,et al.  The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.

[21]  B. Boudailliez,et al.  Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. , 1991, The Journal of clinical endocrinology and metabolism.

[22]  M. Kaye,et al.  Staining of bone for aluminum: use of acid solochrome azurine. , 1990, Kidney international.

[23]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  Brennan,et al.  Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. , 1987, Clinical chemistry.

[25]  A. Freemont,et al.  Detection and distribution of aluminium in bone. , 1984, Journal of clinical pathology.

[26]  G. Delling [Endocrine bone diseases morphology, histomorphometry and differential diagnosis (author's transl)]. , 1975, Veroffentlichungen aus der Pathologie.

[27]  R. Schenk,et al.  Quantitative structural analysis of human cancellous bone. , 1970, Acta anatomica.